Protalix BioTherapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
PLX NYSE American 2836 www.protalix.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Protalix BioTherapeutics, Inc.

Baozun And 2 Other Promising Penny Stocks - Jan 9th, 2026 11:05 am
Protalix BioTherapeutics Letter to Stockholders - Jan 5th, 2026 4:50 am
PLX: Secarna’s Antisense Oligonucleotide Discovery Collaboration - Dec 22nd, 2025 12:15 am
Protalix Biotherapeutics and Secarna Pharmaceuticals Enter into Collaboration and Option Agreement - Dec 17th, 2025 4:50 am
PLX: Protalix Seeks Re-Examination of CHMP Opinion - Nov 17th, 2025 3:27 am
Protalix BioTherapeutics Inc (PLX) Q3 2025 Earnings Call Highlights: Navigating Revenue ... - Nov 13th, 2025 12:05 pm
Protalix: Q3 Earnings Snapshot - Nov 13th, 2025 4:55 am
Protalix BioTherapeutics Reports Third Quarter 2025 Financial and Business Results - Nov 13th, 2025 4:50 am
Protalix BioTherapeutics to Announce Third Quarter 2025 Financial and Business Results on November 13, 2025 - Nov 6th, 2025 4:50 am
Chiesi Global Rare Diseases and Protalix BioTherapeutics Seek Re-examination from the EMA for the Negative Opinion for Elfabrio (pegunigalsidase alfa) Alternative Dosing Regimen of Every Four Weeks in the EU - Nov 3rd, 2025 2:30 pm
3 Compelling Penny Stocks With Market Caps Under $600M - Oct 27th, 2025 6:15 am
Can Protalix (PLX) Turn Regulatory Setbacks Into a Competitive Advantage in Rare Disease Markets? - Oct 19th, 2025 5:14 am
Protalix BioTherapeutics (PLX): Evaluating Valuation After EMA Setback on Elfabrio Dosing Regimen - Oct 18th, 2025 3:11 am
Chiesi Global Rare Diseases and Protalix Biotherapeutics Acknowledge CHMP Negative Opinion on Every Four Week Dosing Regimen of Elfabrio® (pegunigalsidase alfa) in the EU - Oct 17th, 2025 4:58 am
Protalix BioTherapeutics, Inc. (PLX) Gains Investor Confidence With Major Stake Increase - Sep 29th, 2025 4:50 pm
3 Penny Stocks With Market Caps Over $30M To Consider - Sep 16th, 2025 6:05 am
Presenting at the Investor Summit Q3 2025 on September 16; Watch the Live Stream for Free - Sep 16th, 2025 6:00 am
Protalix BioTherapeutics to Present at Investor Summit Virtual - Sep 11th, 2025 8:55 am
Protalix BioTherapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference - Sep 2nd, 2025 4:50 am
PLX: New CFO to Take the Reins - Aug 15th, 2025 11:09 am